Axsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?

Simply Wall St.05-14

Axsome Therapeutics recently reported first-quarter 2026 results, with revenue of US$191.2 million and a net loss of US$64.54 million, and earlier in April received U.S. FDA approval for AUVELITY to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635776935?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-05-14 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635776935","market":"us","top_or_hot":-1,"title":"Axsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>Axsome Therapeutics recently reported first-quarter 2026 results, with revenue of US$191.2 million and a net loss of US$64.54 million, and earlier in April received U.S. FDA approval for AUVELITY to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-axsm-is-up-57-after-auvelity-alzheimers\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-14 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-axsm-is-up-57-after-auvelity-alzheimers><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Axsome Therapeutics recently reported first-quarter 2026 results, with revenue of US$191.2 million and a net loss of US$64.54 million, and earlier in April received U.S. FDA approval for AUVELITY to ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-axsm-is-up-57-after-auvelity-alzheimers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-axsm-is-up-57-after-auvelity-alzheimers","article_id":"2635776935","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-axsm-is-up-57-after-auvelity-alzheimers","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635776935","pubTimestamp":1778725714,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Axsome Therapeutics recently reported first-quarter 2026 results, with revenue of US$191.2 million and a net loss of US$64.54 million, and earlier in April received U.S. FDA approval for AUVELITY to treat agitation associated with dementia due to Alzheimer’s disease, backed by Phase 3 ADVANCE-1 and ACCORD-2 data.\nThe AUVELITY label expansion creates a new opportunity in Alzheimer’s-related agitation, a highly prevalent, costly, and difficult-to-manage symptom, while Axsome prepares a June...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4007":"制药","BK4505":"高瓴资本持仓"},"translate_title":"Axsome Therapeutics(AXSM)在AUVELITY阿尔茨海默氏症焦虑症获得批准并推出后上涨5.7%——牛市情况发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":1.5},"content_text":"Axsome Therapeutics recently reported first-quarter 2026 results, with revenue of US$191.2 million and a net loss of US$64.54 million, and earlier in April received U.S. FDA approval for AUVELITY to treat agitation associated with dementia due to Alzheimer’s disease, backed by Phase 3 ADVANCE-1 and ACCORD-2 data. The AUVELITY label expansion creates a new opportunity in Alzheimer’s-related agitation, a highly prevalent, costly, and difficult-to-manage symptom, while Axsome prepares a June launch supported by an enlarged 630-person sales force and broad expected Medicare Part D coverage. We’ll now examine how AUVELITY’s new Alzheimer’s agitation indication, and Axsome’s expanded commercial push, reshape the company’s investment narrative. We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementAxsome Therapeutics Investment Narrative RecapTo own Axsome today, you have to believe its focused CNS portfolio, led by Auvelity and Sunosi, can eventually support a path to profitability despite ongoing net losses and heavy commercial spend. The new Alzheimer’s agitation label is a clear short term catalyst, but it also amplifies reliance on Auvelity at a time when losses widened to US$64.54 million in Q1 2026, keeping execution and payer pressure as key risks. The most relevant recent development here is the FDA approval of Auvelity for agitation in dementia due to Alzheimer’s disease, supported by the ADVANCE-1 and ACCORD-2 Phase 3 trials. This label expansion slots directly into Axsome’s existing commercial buildout, including the 630 person sales force and broad expected Medicare Part D coverage, and now sits alongside other late stage efforts like solriamfetol and AXS-14 as a core driver of the next phase of catalysts. However, investors should also be aware that... Read the full narrative on Axsome Therapeutics (it's free!)Axsome Therapeutics' narrative projects $2.5 billion revenue and $932.4 million earnings by 2029.Uncover how Axsome Therapeutics' forecasts yield a $266.94 fair value, a 13% upside to its current price.Exploring Other PerspectivesAXSM 1-Year Stock Price Chart Before this approval, the most optimistic analysts were already modeling Axsome’s revenue reaching about US$2.5 billion and earnings of roughly US$1.4 billion by 2028, which is a much more aggressive view than consensus and assumes that late stage programs like AXS 05 in Alzheimer’s agitation all hit their marks, so this new label could either reinforce or challenge that story depending on how the launch actually performs.Explore 8 other fair value estimates on Axsome Therapeutics - why the stock might be worth over 3x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Axsome Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.Contemplating Other Strategies?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Outshine the giants: these 16 early-stage AI stocks could fund your retirement.Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The latest GPUs need a type of rare earth metal called Neodymium and there are only 33 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635776935","isCrawlerRequest":true}